Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

812
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
812
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials.

JAMA network open·2026
Same author

Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets-A New Perspective?

International journal of molecular sciences·2026
Same author

PRS-BC<sub>313</sub> integration for tailored breast cancer prevention in female patients and their healthy relatives.

Journal of medical genetics·2026
Same author

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases.

Archives of gynecology and obstetrics·2026

Related Experiment Video

Updated: Mar 18, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score

Michael Braun1, Oleg Gluz2,3,4, Sherko Kuemmel2,5,6

  • 1Interdisciplinary Breast Center, Department of Obstetrics and Gynecology, RedCross Hospital, Munich, Germany.

Breast Care (Basel, Switzerland)
|March 16, 2026
PubMed
Summary

In HR+/HER2- early breast cancer, risk stratification impacts survival outcomes. Evaluating endocrine treatment response refines prognosis for intermediate-risk patients, aiding treatment decisions.

Keywords:
AbemaciclibBreast neoplasmsKi-67 antigenNeoadjuvant therapyRibociclib

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Related Experiment Videos

Last Updated: Mar 18, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Area of Science:

  • Oncology
  • Clinical Trials
  • Genomics

Background:

  • CDK4/6 inhibitors plus endocrine treatment (ET) improve survival in high-risk HR+/HER2- early breast cancer (eBC).
  • Prognostic factors influence the absolute survival benefit of these treatments.
  • The WSG-ADAPT-HR+/HER2- trial investigated Ki67 response to ET for treatment decisions.

Purpose of the Study:

  • To analyze subgroup outcomes in the WSG-ADAPT-HR+/HER2- trial based on NATALEE and monarchE criteria.
  • To evaluate the prognostic value of risk classifications and ET response in HR+/HER2- eBC.
  • To inform shared decision-making for intermediate-risk patients.

Main Methods:

  • Retrospective analysis of 4365 patients from the WSG-ADAPT-HR+/HER2- trial.
  • Patients were categorized into low, intermediate, and high-risk groups based on clinical and pathological factors, including Ki67 and response to induction ET.
  • Subgroup outcomes were compared between ET and chemotherapy (CTx) subtrials.

Main Results:

  • Risk classifications were prognostic in both ET and CTx subtrials with a median follow-up of 60 months.
  • 5-year invasive disease-free survival (iDFS) and distant DFS (dDFS) rates decreased across risk groups (low > intermediate > high).
  • Intermediate-risk patients meeting NATALEE but not monarchE criteria showed only slightly inferior outcomes compared to the low-risk group.

Conclusions:

  • Endocrine treatment response evaluation can refine prognosis for intermediate-risk HR+/HER2- eBC patients.
  • An absolute benefit of approximately 2% fewer distant DFS events after 5 years could be expected with CDK4/6 inhibitors in this group.
  • Risk stratification and ET response assessment are crucial for optimizing treatment decisions and shared decision-making.